Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092946 | 0.73 | PI4KA (0.31) | — | |
| SCHEMBL1093136 | 0.73 | — | — | |
| SCHEMBL10263958 | 0.73 | — | — | |
| SCHEMBL1093372 | 0.72 | CYP1A2 (0.32) | CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1093245 | 0.72 | EGFR (0.30) | — | |
| SCHEMBL1096657 | 0.69 | — | — | |
| SCHEMBL10195823 | 0.66 | MEN1 (0.34) | MEN1KMT2AGSK3B | |
| SCHEMBL7650714 | 0.64 | NPC1 (0.42) | NPC1CYP3A4CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL8983616 | 0.63 | — | — | |
| SCHEMBL13172843 | 0.62 | PI4KA (0.41) | KDM4ESMN1; SMN2CYP3A4CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | KDM4E 3057/4885MAPT 867/4885SMN1; SMN2 420/4885 |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | KDM4E 2663/4885MAPT 3078/4885SMN1; SMN2 4704/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | KDM4E 3057/4885MAPT 867/4885SMN1; SMN2 420/4885 |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | KDM4E 3057/4885MAPT 867/4885SMN1; SMN2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.